Lamivudin Mylan (Lamivudine)

Lamivudine is taken up by cells and phosphorylated to its active triphosphate form. This active metabolite competes with natural nucleosides for the reverse transcriptase enzyme of HIV and the polymerase of HBV, becoming incorporated into viral DNA and causing premature chain termination, thereby halting viral replication.

The exact dose of Lamivudin Mylan is determined by the prescribing clinician based on the individual’s clinical condition, viral load, renal function, and other factors. Healthcare professionals follow established treatment guidelines and adjust the regimen as needed.

The safety of lamivudine in pregnancy and lactation has not been definitively established. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To request Lamivudin Mylan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lamivudin Mylan belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, offering a well‑characterised safety profile and convenient oral dosing. Compared with newer agents, it may have fewer drug‑interaction concerns but can be combined with other antiretrovirals for a potent regimen. Choice of therapy depends on resistance patterns, patient comorbidities, and guideline recommendations.

Lamivudin Mylan should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Lamivudin Mylan is administered orally, typically as a tablet taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare professional and swallow the tablet whole with water.

Serious risks include lactic acidosis, severe hepatotoxicity, pancreatitis, and hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be educated to seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, severe fatigue, jaundice, or a rash with systemic symptoms.

Lamivudin Mylan is contraindicated in individuals with known hypersensitivity to lamivudine or any of the tablet’s excipients. Caution is also advised for patients with pre‑existing severe liver disease, mitochondrial disorders, or those receiving contraindicated drugs such as didanosine or stavudine.